Akers Biosciences to Present at the Investor Summit on December 17th in Philadelphia

THOROFARE, NJ / ACCESSWIRE / December 10, 2019 / Akers Biosciences, Inc. (NASDAQ:AKER), will be presenting at this year’s Investor Summit on December 17th in Philadelphia.

The Investor Summit will take place at Hotel Monaco, featuring 30 companies and over 200 institutional and retail investors.

About Akers Biosciences, Inc.

Akers Biosciences, Inc. (aka Akers Bio) was founded in 1989, with the objective of developing proprietary, in vitro diagnostic technologies that accelerate the rate at which clinicians, and in some cases consumers, can obtain health information. The tests and sample preparation devices that emerge from our rapid technology platforms are designed to provide the same level of accuracy as traditional laboratory testing methods, but at a fraction of the cost and turn-around time.

The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.

To register as a presenting company please email info@microcapconf.com.

To request complimentary investor registration: please visit our website at www.microcapconf.com.

News Compliments of ACCESSWIRE

FOR MORE INFORMATION

Please visit: www.microcapconf.com

Or, contact Ashley Allard at ashley@microcapconf.com

SOURCE: Akers Biosciences, Inc.

View source version on accesswire.com:
https://www.accesswire.com/569750/Akers-Biosciences-to-Present-at-the-Investor-Summit-on-December-17th-in-Philadelphia

Staff

Recent Posts

Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates

ELI-002 2P clinical immunogenicity data were accepted for a poster presentation at the AACR Annual…

15 mins ago

Molecular Templates, Inc. Reports Fourth Quarter 2023 Financial Results and Business Update

AUSTIN, Texas, March 29, 2024 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or…

15 mins ago

KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by…

15 mins ago

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading…

15 mins ago

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year…

15 mins ago

Vision Sensing Acquisition Corp. Announces Intention to Extend Period to Consummate Initial Business Combination to May 3, 2024

MIAMI, March 29, 2024 (GLOBE NEWSWIRE) -- Vision Sensing Acquisition Corp. (NASDAQ: VSACU, VSAC, VSACW)…

15 mins ago